Recent reports from scientist at the Mt. Sinai School of Medicine indicate that diabetes drugs could have a significant impact on Alzheimer’s disease . The study builds on previous reports that people with diabetes face a higher risk of developing Alzheimer’s disease .
The results were presented on Monday at the International Conference on Alzheimer’s Disease in Chicago. Researcher Michal Beeri and team researched samples from almost 250 patients from the Mt. Sinai Brain Bank.
Beeri was reported as commenting: “The group on combination therapy had a very, very low load of neuritic plaques. Their brains looked almost like normal people. The medications did not, however, do much to reduce the number of tangles — the fibrous nerve nets that are another defining characteristic of the memory-robbing disease — in the brains of Alzheimer’s patients.”
She reportedly continued: “Our hypothesis is that with the combination therapy, the gene and protein expression of these Alzheimer’s patients might be close to that of normal people who don’t have Alzheimer’s at all. I am hoping that this sheds light on a potentially new mechanism for insulin’s role in controlling the disease and lead us to new therapies.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…